• About us
  • Contact Us
  • Submit a Press Release
Wednesday, February 8, 2023
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
South-Africana
No Result
View All Result
Submit PR
  • AFRICA
    Spotcovery, ambayo hutumika kama daraja kati ya Wamarekani Weusi na Waafrika, imezindua zana ya uboreshaji kwenye tovuti.

    Spotcovery, ambayo hutumika kama daraja kati ya Wamarekani Weusi na Waafrika, imezindua zana ya uboreshaji kwenye tovuti.

    Spotcovery, ambayo hutumika kama daraja kati ya Wamarekani Weusi na Waafrika, imezindua zana ya uboreshaji kwenye tovuti.

    Spotcovery, intermediaire entre les Afro-Américains et les Africains, a lancé un outil d’optimisation sur le site

    Spotcovery, Which Serves as a Bridge Between African Americans and Africans, has Launched Optimization Tool on Site

    Spotcovery, Which Serves as a Bridge Between African Americans and Africans, has Launched Optimization Tool on Site

    The Water Project Deepens its Commitment to Clean Water to Vihiga County, Kenya

    Mradi wa Maji waiimarisha ahadi yake ya kusafisha maji katika Kaunti ya Vihiga, Kenya

  • Botswana

    Botswana increases 2022 economic growth forecast to 6.7% – Reuters.com

    Scatec refinances US$100 million facility – PV-Tech

    Wide Support For New WHO ‘Best Buys’ To Address NCDs – Health Policy Watch

    Three Youth-Led African Agritech Businesses Receive Investment To Help Scale Up African Agriculture – Forbes

  • Eswatini

    Ngoma over the moon with spa and restaurant business – Caj News Africa

    Why Russia Is Failing To Gain Influence In Africa – Yahoo Finance

    Eswatini: Everything for patients – ZAWYA

    Combating the water crisis in Eswatini in southern Africa – Church News

  • Lesotho

    Meet the female cycling addicts – Business Daily

    Lesotho Increases Fruit Production – ZAWYA

    South Africa: President Ramaphosa encouraged by progress achieved in the Kingdom of Lesotho – ZAWYA

    Movers & Shakers: Five promotions at Health and Aged Care – The Mandarin

  • Namibia

    Local mining sector to showcase investment opportunities at SA … – Namibia Economist

    Osino receives offers to finance Twin Hills – Namibian

    /Ae//Gams Festival set for April – Participation applications now open – Namibia Economist

    Zooming in on Polycystic ovary syndrome – Namibia Economist

  • South Africa

    South Africa's biggest retailer is offering all-inclusive bursaries for … – BusinessTech

    EMERGING MARKETS-Turkey's lira hits fresh low; Sino-U.S. tensions weigh on China shares – Yahoo Finance

    South Africa’s biggest retailer is offering all-inclusive bursaries for 2023 – here’s how to apply – BusinessTech

    Lesotho, South Africa discuss issues of Mutual Interest – African Business

    Big changes for food labels in South Africa – including sugar warnings and an end to ‘super-food’ – BusinessTech

    Discount retailer Pepkor first quarter sales up 6.5% on store expansion

    Trending Tags

    • Press releases

      UHT Processing Market Statistics, Growth, Trends & Forecasts

      Industrial PC Market Worth $6.6 billion in 2028 at a CAGR of 5.5%

      Automotive Adhesive Tapes Market Size is projected to reach USD 12.1 Billion By 2026

      Automotive Adhesive Tapes Market Size is projected to reach USD 12.1 Billion By 2026

      Fatty Amines Market Global Analysis by Top Key Players Focusing on Growth Strategies and Upcoming Trends 2024

      Fatty Amines Market Global Analysis by Top Key Players Focusing on Growth Strategies and Upcoming Trends 2024

      Data Center Power Market Projected to Gain $26.1 billion by 2025

      Fiber Cement Market – Potential Opportunities and Company Analysis

      Fiber Cement Market – Potential Opportunities and Company Analysis

      Trending Tags

      • AFRICA
        Spotcovery, ambayo hutumika kama daraja kati ya Wamarekani Weusi na Waafrika, imezindua zana ya uboreshaji kwenye tovuti.

        Spotcovery, ambayo hutumika kama daraja kati ya Wamarekani Weusi na Waafrika, imezindua zana ya uboreshaji kwenye tovuti.

        Spotcovery, ambayo hutumika kama daraja kati ya Wamarekani Weusi na Waafrika, imezindua zana ya uboreshaji kwenye tovuti.

        Spotcovery, intermediaire entre les Afro-Américains et les Africains, a lancé un outil d’optimisation sur le site

        Spotcovery, Which Serves as a Bridge Between African Americans and Africans, has Launched Optimization Tool on Site

        Spotcovery, Which Serves as a Bridge Between African Americans and Africans, has Launched Optimization Tool on Site

        The Water Project Deepens its Commitment to Clean Water to Vihiga County, Kenya

        Mradi wa Maji waiimarisha ahadi yake ya kusafisha maji katika Kaunti ya Vihiga, Kenya

      • Botswana

        Botswana increases 2022 economic growth forecast to 6.7% – Reuters.com

        Scatec refinances US$100 million facility – PV-Tech

        Wide Support For New WHO ‘Best Buys’ To Address NCDs – Health Policy Watch

        Three Youth-Led African Agritech Businesses Receive Investment To Help Scale Up African Agriculture – Forbes

      • Eswatini

        Ngoma over the moon with spa and restaurant business – Caj News Africa

        Why Russia Is Failing To Gain Influence In Africa – Yahoo Finance

        Eswatini: Everything for patients – ZAWYA

        Combating the water crisis in Eswatini in southern Africa – Church News

      • Lesotho

        Meet the female cycling addicts – Business Daily

        Lesotho Increases Fruit Production – ZAWYA

        South Africa: President Ramaphosa encouraged by progress achieved in the Kingdom of Lesotho – ZAWYA

        Movers & Shakers: Five promotions at Health and Aged Care – The Mandarin

      • Namibia

        Local mining sector to showcase investment opportunities at SA … – Namibia Economist

        Osino receives offers to finance Twin Hills – Namibian

        /Ae//Gams Festival set for April – Participation applications now open – Namibia Economist

        Zooming in on Polycystic ovary syndrome – Namibia Economist

      • South Africa

        South Africa's biggest retailer is offering all-inclusive bursaries for … – BusinessTech

        EMERGING MARKETS-Turkey's lira hits fresh low; Sino-U.S. tensions weigh on China shares – Yahoo Finance

        South Africa’s biggest retailer is offering all-inclusive bursaries for 2023 – here’s how to apply – BusinessTech

        Lesotho, South Africa discuss issues of Mutual Interest – African Business

        Big changes for food labels in South Africa – including sugar warnings and an end to ‘super-food’ – BusinessTech

        Discount retailer Pepkor first quarter sales up 6.5% on store expansion

        Trending Tags

        • Press releases

          UHT Processing Market Statistics, Growth, Trends & Forecasts

          Industrial PC Market Worth $6.6 billion in 2028 at a CAGR of 5.5%

          Automotive Adhesive Tapes Market Size is projected to reach USD 12.1 Billion By 2026

          Automotive Adhesive Tapes Market Size is projected to reach USD 12.1 Billion By 2026

          Fatty Amines Market Global Analysis by Top Key Players Focusing on Growth Strategies and Upcoming Trends 2024

          Fatty Amines Market Global Analysis by Top Key Players Focusing on Growth Strategies and Upcoming Trends 2024

          Data Center Power Market Projected to Gain $26.1 billion by 2025

          Fiber Cement Market – Potential Opportunities and Company Analysis

          Fiber Cement Market – Potential Opportunities and Company Analysis

          Trending Tags

          Submit PR
          No Result
          View All Result
          South-africana
          Submit PR
          Home Press Releases

          Saxagliptin Market Size Estimated to Reach $255 Million by 2027

          admin by admin
          March 19, 2022
          in Press Releases
          Saxagliptin Market Size Estimated to Reach $255 Million by 2027
          Share on FacebookShare on Twitter


           


          Saxagliptin Market

          (EMAILWIRE.COM, March 19, 2022 ) Saxagliptin Market size is estimated to reach $255 million by 2027, growing at a CAGR of 4.17% during the forecast period 2022-2027. Saxagliptin is a medication utilized to treat type 2 diabetes mellitus. It is applied in conjunction with a healthy diet and everyday exercise to curb blood sugar levels. This assists in averting severe complexities of diabetes like kidney damage and blindness. No investigations directly examined in contrast with the impacts of including saxagliptin versus a basal insulin therapy on top of metformin monotherapy, an alternative therapy proposed as tier 1 in the ADA-EASD consensus statement. Therefore the investigation showed that metformin plus saxagliptin could be included with insulin therapy in the handling of patients with T2DM (Type 2 Diabetes Mellitus), but did not examine in contrast saxagliptin with basal insulin on top of baseline metformin monotherapy. Saxagliptin (Onglyza) is a greatly powerful, orally bioavailable, reversible dipeptidyl peptidase IV (DPPIV) inhibitor endorsed by the U.S. Food and Drug Administration (FDA) in 2009 for the treatment of type 2 diabetes mellitus. Constant with the mechanism, treatment with saxagliptin also resulted in statistically important reductions in Post Prandial Glucose (PPG) that were related to higher boosts in postprandial insulin and C-peptide AUC levels versus metformin plus placebo, recommending that saxagliptin enhanced postprandial cell responsiveness to glucose. The glucose tolerance test also termed the oral glucose tolerance test, evaluates the body’s response to sugar (glucose). The oral glucose tolerance test may be utilized to screen for type 2 diabetes. Typically, a modified version of the oral glucose tolerance test is utilized to diagnose gestational diabetes — a kind of diabetes that progresses at the time of pregnancy. In one trial, a lymphocyte count of 750 cells/mcL or lower appeared in 0.5% of saxagliptin 2.5-mg recipients, in 1.5% of saxagliptin 5-mg recipients, and in 0.4% of placebo recipients. Nil boost in risk for cardiovascular disease was observed in trials including comparatively reduced–risk patients. The expanding predominance of diabetes requiring extensive application of screening tests like oral glucose tolerance tests and the complications in substitute therapies for diabetes is set to drive the Saxagliptin Market. The ingenious R&D activities in the area of diabetes therapeutics are set to propel the growth of the Saxagliptin Market during the forecast period 2022-2027. This represents the Saxagliptin Industry Outlook.

          Saxagliptin Market Segment Analysis – By Dosage:

          The Saxagliptin Market based on dosage can be further segmented into 2.5 Mg and 5 Mg. The 2,5 Mg Segment held the largest market share in 2021. This growth is owing to the increasing application of dipeptidyl peptidase iv inhibitor termed Saxagliptin in its 2.5 Mg Oral tablet form for treatment of type 2 diabetes mellitus. The capability of Saxagliptin to be utilized in conjunction with diet and exercise to curb blood sugar in mature grown-ups with type diabetes is further propelling the growth of the genome engineering segment.

          Furthermore, the 5 Mg segment is estimated to grow with the fastest CAGR of 4.8% during the forecast period 2022-2027 owing to the heightening application of Onglyza 5 mg film-coated tablets where every tablet includes 5 mg saxagliptin (as hydrochloride) which is a dipeptidyl peptidase iv inhibitor.

          Saxagliptin Market Segment Analysis – By Distribution Channel

          The Saxagliptin Market based on distribution channels can be further segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Online Pharmacies Segment held the largest market share in 2021. This growth is owing to the increasing utilization of online pharmacies for the sale of dipeptidyl peptidase iv inhibitors like saxagliptin amidst the global lockdowns and stay-at-home restrictions in the wake of the COVID-19 pandemic. The ease of use of online channels like MedPlus and Prescription Hope while staying in the comfort of home is further propelling the growth of this segment.

          Furthermore, the Hospital Pharmacies segment is estimated to grow with the fastest CAGR of 4.9% during the forecast period 2022-2027 owing to the burgeoning utilization of hospital pharmacies for the sale of dipeptidyl peptidase iv inhibitors like saxagliptin as life returns to pre-pandemic normalcy.

          Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=502127

          Report Price: $ 4500 (Single User License)

          Saxagliptin Market Segment Analysis – By Geography

          The Saxagliptin Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Saxagliptin Market) held the largest share with 36.4% of the overall market in 2021. The growth of this region is owing to the increasing predominance of type 2 diabetes requiring the increased application of dipeptidyl peptidase iv inhibitors like Saxagliptin and an enormous population of the elderly in the region. The upsurge in government financing and soaring healthcare spending on R&D are further propelling the growth of the Saxagliptin Market in the North American region.

          Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the proliferating population in countries like India and China in the region. The expanding government financing and the surging spending on healthcare in conjunction with the heightening application of dipeptidyl peptidase iv inhibitors like Saxagliptin in the region are fuelling the progress of the Saxagliptin Market in the Asia-Pacific region.

          Saxagliptin Market Drivers

          Increasing Predominance Of Diabetes Is Projected To Drive The Growth Of Saxagliptin Market:

          As per World Health Organization (WHO), diabetes was the ninth chief cause of demise with an approximated 1.5 million demises directly brought about by diabetes in 2019. Further updates from WHO indicate that a healthy diet, daily physical activity, keeping up normal body weight, and refraining from the usage of tobacco are ways to avert or restrict the beginning of type 2 diabetes. Saxagliptin, marketed under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic medication) of the dipeptidyl peptidase iv (DPP-IV) inhibitor class. Metformin monotherapy may also be performed for the treatment of metformin monotherapy. Saxagliptin restricts DPP-IV, an enzyme accounting for the disintegration of GLP-1. By postponing GLP-1 degeneration, saxagliptin boosts the action of insulin while also restraining the discharge of glucagon. This results in a minimization in raised blood glucose levels that characterizes type 2 diabetes. The surging application of Saxagliptin to treat type 2 diabetes is fuelling the growth of the Saxagliptin Market during the forecast period 2022-2027.

          Surging Application Of Saxagliptin For Treatment Of Obesity Is Expected To Boost The Demand Of Saxagliptin:

          As per World Health Organization (WHO), 1.9 million mature grown-ups globally were overweight in 2016, with 650 million obese. Obesity is a principal cause of type 2 diabetes. ACCES (Acute and Chronic Effects of Saxagliptin) is an arbitrary, placebo-controlled, double-blind, controlled phase 2 pilot investigation that looks to evaluate obese patients with diminished glucose tolerance and the acute effects consequent to 12 weeks of saxagliptin treatment which is a medication of dipeptidyl peptidase iv (DPP-IV) inhibitor class on glucose levels at fasting and postprandially following breakfast. The investigation was conducted at Jean Verdier University Hospital in Bondy, France. It was endorsed by both the local ethics committee and by the French National Agency for Drug Security. The investigation had two parts. The first part was to investigate the acute and chronic impacts of saxagliptin vs placebo on glucose tolerance. The second was the acute and chronic effect of saxagliptin vs. placebo on micro and macrovascular parameters. Based on the investigation, saxagliptin has positive metabolic advantages in obese glucose-intolerant patients. It can decrease postprandial plasma glucose levels without having harmful impacts on body weight. Saxagliptin also enhanced the glycemic status of the patient post 12 weeks of treatment. For most of the patients in this investigation, glucose levels normalized. The extensive application of Saxagliptin for the treatment of obesity is therefore driving the growth of the Saxagliptin Market during the forecast period 2022-2027.

          Direct Purchase link @ https://www.industryarc.com/purchasereport.php?id=502127

          Saxagliptin Market Challenges

          Limitations Of Application Of Saxagliptin Present Challenges To The Growth Of The Saxagliptin Market:

          Saxagliptin is not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, owing to its ineffectiveness in these settings. Saxagliptin tablets should not be ruptured or divided. Raised hazard of hypoglycemia with concomitant sulfonylureas, dose minimization may be essential. Raised serum levels with CYP3A4/5 inhibitors like atazanavir, ketoconazole, nefazodone, and ritonavir. Concomitant CYP3A4 inducers like carbamazepine and phenobarbital may minimize the glycaemic reducing impact of saxagliptin. Side effects include pancreatitis, heart failure, hypoglycemia with concomitant application of sulfonylurea or insulin, hypersensitivity reactions, serious and disabling arthralgia, and bullous pemphigoid. The limitations of the application of Saxagliptin are hampering the growth of the Saxagliptin Market.

          Saxagliptin Industry Outlook

          Product launches, mergers and acquisitions, Joint ventures, and geographical expansions are key strategies adopted by players in the Market. Saxagliptin top 10 companies include:

          Bristol-Myers Squibb Company
          AstraZeneca Plc
          Jubilant Life Sciences Limited
          Centaur Pharmaceuticals
          Teva Pharmaceutical Industries
          Prajna Generics
          Wellona Pharma
          Dr Reddy’s Laboratories Limited Hetero Drugs Limited
          Sanofi

          Acquisitions/Product Launches:

          In December 2020, AstraZeneca, filed a definitive agreement to gain U.S. biotechnology group Alexion Pharmaceuticals for $39bn, turning it into the largest deal struck by a pharmaceutical firm since the commencement of the pandemic. Under the terms of the deal, Alexion shareholders will accept $60 in cash and 2.1243 AstraZeneca’s shares for each Alexion’s share. The transaction values Alexion at $175 per share, a 48% premium to its closing price 5 days prior to the declaration.

          In November 2020, Bristol Myers Squibb declared that it has favorably finished its acquisition of MyoKardia, Inc. in an all-cash transaction for nearly $13.1 billion. With the accomplishment of the acquisition, MyoKardia shares have stopped trading on the NASDAQ Global Select Market and MyoKardia is presently a completely-owned subsidiary of Bristol Myers Squibb. By way of the transaction with MyoKardia, Bristol Myers Squibb acquires mavacamten, a possible first-in-class cardiovascular medication for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”), an incessant heart ailment with great morbidity and patient effect.

          In September 2020, Centaur Pharmaceuticals declared the introduction of a New Chemical Entity (NCE) – WOXheal. With its two-fold mechanism of activity, WOXheal is a rare product in diabetic foot ulcer treatment. It will rescue millions of diabetic patients who have to endure foot amputation worldwide.

          Key Takeaways

          Geographically, North America Saxagliptin Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing population of the elderly requiring surging application of screening tests like oral glucose tolerance tests and the surging sedentary lifestyle in the North American region.

          Saxagliptin Market growth is being driven by the proliferating government financing and an upsurge in the intake of junk food subsequently requiring screening tests like oral glucose tolerance tests. However, Saxagliptin may bring about complexities like stroke and heart attack and this is one of the major factors hampering the growth of the Saxagliptin Market.

          Saxagliptin Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Saxagliptin Market report.

          Related Report

          Diabetes Devices Market
          https://www.industryarc.com/Research/Diabetes-Devices-Market-Research-503719

          For more Lifesciences and Healthcare Market reports, please click here

          About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.



          Source link

          Previous Post

          The Lateral Flow Assay Test Market to Go the Virtual Reality Ways

          Next Post

          ACNE Medication Market Size Estimated to Reach $12.8 Million by 2027

          Related Posts

          Press Releases

          UHT Processing Market Statistics, Growth, Trends & Forecasts

          February 3, 2023
          Press Releases

          Industrial PC Market Worth $6.6 billion in 2028 at a CAGR of 5.5%

          February 3, 2023
          Automotive Adhesive Tapes Market Size is projected to reach USD 12.1 Billion By 2026
          Press Releases

          Automotive Adhesive Tapes Market Size is projected to reach USD 12.1 Billion By 2026

          February 3, 2023
          Fatty Amines Market Global Analysis by Top Key Players Focusing on Growth Strategies and Upcoming Trends 2024
          Press Releases

          Fatty Amines Market Global Analysis by Top Key Players Focusing on Growth Strategies and Upcoming Trends 2024

          February 3, 2023
          Press Releases

          Data Center Power Market Projected to Gain $26.1 billion by 2025

          February 3, 2023
          Press Releases

          Aviation Fuel Market Worth $696.2 Billion by 2030 at a CAGR of 13.7%

          February 2, 2023

          Discussion about this post

          LATEST NEWS

          Botswana increases 2022 economic growth forecast to 6.7% – Reuters.com

          February 6, 2023

          Scatec refinances US$100 million facility – PV-Tech

          February 6, 2023

          Wide Support For New WHO ‘Best Buys’ To Address NCDs – Health Policy Watch

          February 6, 2023

          Three Youth-Led African Agritech Businesses Receive Investment To Help Scale Up African Agriculture – Forbes

          February 6, 2023

          About

          South Africana™ reports and aggregates business, socio-economic, Tech and industrial news on Southern African countries.

          We provide press release distribution to media outlets in Africa including Botswana, Eswatini, Lesotho, Namibia and South Africa. To submit a press release today, contact us.

          Categories

          BOTSWANA

          ESWATINI

          LESOTHO

          NAMIBIA

          SOUTH AFRICA

          PRESS RELEASES

          Recent Post

          Recent Posts
          • Botswana increases 2022 economic growth forecast to 6.7% – Reuters.com
          • Scatec refinances US$100 million facility – PV-Tech
          • Wide Support For New WHO ‘Best Buys’ To Address NCDs – Health Policy Watch

          Subscribe to Our Newsletter

            Share Us

            Share on facebook
            Share on twitter
            Share on linkedin
            Share on pinterest
            South Africana™ is part of GroupWeb Media Network. © 2023 GroupWeb Media LLC
            No Result
            View All Result
            • AFRICA
            • Botswana
            • Eswatini
            • Lesotho
            • Namibia
            • South Africa
            • Press releases

            © 2022 Copyright SOUTH-AFRICANA